Clinical Development

Ongoing: 24-week multicenter, double-blinded, placebo-controlled dose range finding Phase 2b study to determine if multiple doses of RTB101 alone or in combination with RAD001 decrease the incidence of respiratory tract infections (RTI) in elderly patients at increased risk of RTI-related morbidity and mortality.  resTORbio plans to complete the study during the second half of 2018.

Keep checking back with us for updates on ongoing and new clinical studies.